NCCN Guidelines for Patients® Version Updates: Non-Small Cell Lung Cancer

Following are the major updates that were included in the NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer, Version 1.2015

  • Part 2 – Assessing lung nodules
    • More information has been added to explain how nodules are assessed for cancer.
      • Page 15
        • Which types of doctors should be on your assessment team is explained.
      • Page 21
        • Choices of how and when the nodule will be assessed for cancer are explained.
  • Part 3 – Lung cancer staging
    • Page 24
      • More information has been added to explain the staging plan for lung cancer.
  • Part 4 – Treatment planning
    • Page 33
      • The use of a PET/CT scan to find the best site to test for cancer that is spreading fast has been added.
    • Page 38
      • Proteomic testing has been added.
  • Part 5 – Overview of cancer treatments
    • Page 49
      • New drugs to treat lung cancer have been added to the chart.
    • Pages 50–51
      • Descriptions of new targeted therapy and immunotherapy drugs have been added.
  • Part 6 – Treatment guide: One primary tumor
    • Pages 60, 66, 76
      • LDCT (low-dose computed tomography) without contrast is recommended for the survivorship care plan if CT results are normal for two years.
    • Pages 80–81
      • Ceritinib has been added as a second-line treatment for lung cancer with an ALK gene rearrangement.
    • Pages 82–85
      • New drug treatments have been added for lung cancers with normal or unknown EGFR and ALK gene status.
    • Page 83
      • An explanation of when proteomic testing can be used has been added.
  • Part 7 – Treatment guide: Multiple primary tumors
    • Pages 90, 92
LDCT (low-dose computed tomography) without contrast is recommended for the survivorship care plan if CT results are normal for two years.